Prevalence and clinical impact of actionable genomic alterations in non–clear cell renal cell carcinoma: A review of NGS-based trials and real-world data. Article

Bastos, Bruno R, Schwartz, Michael A, Forghani, Irman et al. (2026). Prevalence and clinical impact of actionable genomic alterations in non–clear cell renal cell carcinoma: A review of NGS-based trials and real-world data. . JOURNAL OF CLINICAL ONCOLOGY, 44(7_suppl), 556-556. 10.1200/jco.2026.44.7_suppl.556

cited authors

  • Bastos, Bruno R; Schwartz, Michael A; Forghani, Irman; Cusnir, Mike; Barrientos, Jacqueline Claudia; Simkins, Aron; Blaustein, Arnold S; Bhandari, Akshay; Nieder, Alan; Borregales, Leonardo; Weizer, Alon; Brauchle, Yelida; Goya Balaguer, Evelyn; Gligich, Oleg

authors

publication date

  • March 1, 2026

published in

keywords

  • 3 Good Health and Well Being
  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Biotechnology
  • Cancer
  • Cancer Genomics
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Genetics
  • Health Disparities
  • Health Disparities and Racial or Ethnic Minority Health Research
  • Human Genome
  • Immunotherapy
  • Kidney Disease
  • Orphan Drug
  • Precision Medicine
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 556

end page

  • 556

volume

  • 44

issue

  • 7_suppl